# PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

> **NCT01266096** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Newly Diagnosed or Recurrent Metastatic Melanoma Patients
- Malignant Brain Tumors

## Interventions

- **DRUG:** PET scan with 124I-cRGDY-PEG-dots

## Key facts

- **NCT ID:** NCT01266096
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266096, "PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01266096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*